Organoids produced from patients with head and neck cancer (HNC) were used to create a biobank by researchers from the Organoid group (Hubrecht Institute) and UMC Utrecht. They used this biobank to validate known HNC indicators, and they discovered that therapy responses in organoids matched
The researchers created new human organoid models of fatty liver disease. They used these models to shed light on drug responses and built a CRISPR-screening platform to find new disease mediators and potential therapeutic targets. These models will aid in the testing and development of nove